Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study

Trial Profile

Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Guillain-Barre syndrome
  • Focus Therapeutic Use
  • Acronyms ICA-GBS
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 15 Mar 2017 Status changed from recruiting to discontinued.
    • 06 Nov 2015 Accrual to date is 16% according to United Kingdom Clinical Research Network record
    • 15 Nov 2014 Accrual to date is 3% according to United Kingdom Clinical Research Network record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top